Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin in Diabetic Peripheral Neuropathy
NCT05162690Phase 3Unknown
- Sponsor
- Post Graduate Institute of Medical Education and Research
- Start
- May 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in diabetic peripheral neuropathy (DPN) comparing Dapagliflozin Arm with Placebo Arm (2 arms). Primary endpoint: Intraepithelial nerve fiber density at 24 weeks. Status: unknown.
02
Drugs
dapagliflozin
03
Conditions
diabetic peripheral neuropathy (DPN)
Beyond the preview
Go deeper on NCT05162690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05162690.